Valeant Pharmaceuticals today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co. to develop and commercialize products containing a new chemical entity, KP-470,  an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.   Under the terms of the licensing agreement, Kaken has granted Valeant an exclusiv...